nlrp3 inhibitor dfv890
nlrp3 inhibitor dfv890: 4 clinical trials tracked.
nlrp3 inhibitor dfv890 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about nlrp3 inhibitor dfv890, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (4)
A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in an Adult Population With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Primary endpoint: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model
A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
Primary endpoint: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model
A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Primary endpoint: Incidence of Dose-limiting Toxicities (DLTs)
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis
Primary endpoint: Change From Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Subscale